Adaptimmune Therapeutics (NASDAQ:ADAP) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note released on Friday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Several other analysts also recently issued reports on the company. Guggenheim decreased their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Scotiabank decreased their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday, March 21st. Jones Trading cut Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 11th. Barclays cut their price objective on Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating for the company in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company cut their price objective on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1.52.

Adaptimmune Therapeutics Stock Performance

ADAP opened at $0.28 on Friday. The company has a market cap of $71.48 million, a PE ratio of -1.26 and a beta of 2.86. The stock has a 50-day moving average of $0.28 and a 200-day moving average of $0.50. Adaptimmune Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.48. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). The company had revenue of $7.29 million during the quarter, compared to the consensus estimate of $6.55 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. As a group, equities research analysts forecast that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Large investors have recently made changes to their positions in the business. Two Sigma Investments LP raised its holdings in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 19,146 shares in the last quarter. Virtu Financial LLC raised its holdings in Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 21,688 shares in the last quarter. Invesco Ltd. raised its holdings in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 58,000 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.